pre-IPO PHARMA

COMPANY OVERVIEW

ArmaGen, Inc., is a privately held biotechnology company focused on developing groundbreaking therapies for severe neurological disorders. The company is developing a robust pipeline of innovative therapies for the treatment of lysosomal storage disorders including neurological symptoms such as Hurler syndrome (MPS I), Hunter syndrome (MPS II), metachromatic leukodystrophy, Sanfilippo A and B syndromes, as well as other diseases with severe CNS manifestations. ArmaGen's pipeline is based on decades of scientific leadership in engineering therapies to cross the blood-brain barrier and a dominant intellectual property portfolio. The company is advancing its pipeline through licensing and collaboration agreements, in-house development programs, and other partnering opportunities.


LOCATION

  • Calabasas, CA, USA

  • THERAPEUTIC AREAS

  • Rare Diseases

  • WEBSITE

    https://armagen.com/


    CAREER WEBSITE

    https://armagen.com/careers/


    SOCIAL MEDIA


    INVESTORS

    boehringer-ingelheim-venture-fund mitsui-global-investments shire takeda-ventures

    PRESS RELEASES


    Apr 27, 2020

    JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc.


    Aug 2, 2018

    ArmaGen Receives U.S. Orphan Drug Designation for AGT-184


    Jul 10, 2018

    ArmaGen's AGT-181 52-Week Phase 1/2 Proof-of-Concept Study Results Published in Orphanet Journal of Rare Diseases


    Feb 8, 2018

    ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I


    Nov 30, 2017

    ArmaGen's AGT-181 Granted Fast Track Designation for the Treatment of Hurler Syndrome (MPS I)


    For More Press Releases


    Google Analytics Alternative